This positive CHMP opinion establishes amivantamab as a new option, and the first fully-human EGFR-MET bispecific antibody, in the first-line treatment of EGFR exon 20 insertion-mutated NSCLC ...
Sen. Bernie Sanders, I-Vermont, is taking Novo Nordisk to task for allegedly turning its blockbuster GLP-1s Ozempic and Wegovy into “luxury goods.”
Doctors have for the first time released details of their spending on a major clinical trial, demonstrating that the true cost of developing a medicine may be far less than the billions of dollars claimed by the pharmaceutical industry.
Cidara regains rights to flu med after Janssen makes good on promise to divest
PBIRx Growth Fueled by Johnson & Johnson ERISA Lawsuit
Flindr Therapeutics has secured €20 million ($21 million) in a Series A raise aimed at advancing its lead program through an IND application and growing its pipeline of small-molecule cancer drugs.
Johnson & Johnson to Participate in the Bernstein’s 40th Annual Strategic Decisions Conference (SDC)
BEERSE, BELGIUM (22 April 2024) – Janssen-Cilag International NV, a Johnson & Johnson company, announced today that the European Commission (EC) has approved a Type II variation for CARVYKTI®? (ciltacabtagene autoleucel; cilta-cel). This latest approval is for the treatment of adult patients with relapsed and refractory multiple myeloma (RRMM), who have received at least one prior therapy, including an immunomodulatory agent (IMiD) and a proteasome inhibitor (PI), have demonstrated disease progression on the last therapy, and are refractory to lenalidomide.1
A cancer victim's family alleged J&J and Kenvue’s predecessor firm sold their talcum-based baby powder knowing it was tainted with asbestos.
WHO likely to issue wider alert on contaminated J&J cough syrup